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Abstract 
Background: Type 2 diabetes mellitus is associated strongly with an increased risk of micro‑ and macro‑vascular 
complications, leading to impaired quality of life and shortened life expectancy. In addition to appropriate glycemic 
control, multi‑factorial intervention for a wide range of risk factors, such as hypertension and dyslipidemia, is crucial 
for management of diabetes. A recent cardiovascular outcome trial in diabetes patients with higher cardiovascular 
risk demonstrated that a SGLT2 inhibitor markedly reduced mortality, but not macro‑vascular events. However, to 
date there is no clinical evidence regarding the therapeutic effects of SGLT2 inhibitors on arteriosclerosis. The ongo‑
ing PROTECT trial was designed to assess whether the SGLT2 inhibitors, ipragliflozin, prevented progression of carotid 
intima‑media thickness in Japanese patients with type 2 diabetes mellitus.
Methods: A total of 480 participants with type 2 diabetes mellitus with a HbA1c between 6 and 10 % despite receiv‑
ing diet/exercise therapy and/or standard anti‑diabetic agents for at least 3 months, will be randomized systemati‑
cally (1:1) into either ipragliflozin or control (continuation of conventional therapy) groups. After randomization, 
ipragliflozin (50–100 mg once daily) will be added on to the background therapy in participants assigned to the 
ipragliflozin group. The primary endpoint of the study is the change in mean intima‑media thickness of the common 
carotid artery from baseline to 24 months. Images of carotid intima‑media thickness will be analyzed at a central core 
laboratory in a blinded manner. The key secondary endpoints include the change from baseline in other parameters 
of carotid intima‑media thickness, various metabolic parameters, and renal function. Other cardiovascular functional 
tests are also planned for several sub‑studies.
Discussion: The PROTECT study is the first to assess the preventive effect of ipragliflozin on progression of carotid 
atherosclerosis using carotid intima‑media thickness as a surrogate marker. The study has potential to clarify the pro‑
tective effects of ipragliflozin on atherosclerosis.
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Background
Type 2 diabetes mellitus (T2DM) is characterized by pro-
longed systemic insulin resistance, resultant impaired 
insulin insufficiency, and life-threatening micro- and 
macro-vascular complications [1–4]. The risk of car-
diovascular (CV) disease is already increased in the 
pre-diabetic state of impaired glucose tolerance (IGT) 
and is associated to a greater degree with impaired fast-
ing and/or 2-h plasma glucose than with HbA1c levels 
[5–8]. Abnormal glycemic metabolism therefore has 
a central role in diabetic pathophysiology. However, 
whether glucose-lowering treatments reduce the risk of 
future CV events still remains controversial, despite the 
legacy-effect of long-term intensive glycemic interven-
tion [9–11]. Given the multi-factorial nature of T2DM 
progression, early medical intervention using a compre-
hensive approach according to an individual’s medical 
background needs to be emphasized in the management 
of the disorders [12, 13]. However, relevant risk factors 
are often not controlled optimally, and no conventional 
anti-diabetic agents can easily achieve such therapeutic 
goals. Given the worldwide increase in the number of 
patients with the metabolic syndrome including obesity 
and diabetes [14, 15], early establishment of therapeu-
tic strategies to prevent the subsequent occurrence of 
obesity/diabetes-related CV complications is urgently 
required.
Sodium glucose cotransporter 2 (SGLT2) inhibitors 
are novel glucose-lowering agents that increase urinary 
glucose excretion by modulating selective inhibition of 
SGLT2 in the proximal renal tubule [16]. SGLT2 inhibi-
tors alleviate glucotoxicity in an insulin-independent 
manner and improve beta-cell dysfunction, and therefore 
may have indirect metabolic benefits [17]. Of the SGLT2 
inhibitors, ipragliflozin was developed in Japan. There 
is evidence that ipragliflozin has the favorable meta-
bolic effects, including improved glycemic control, and 
decreased blood pressure (BP), body weight (BW), and 
visceral adipose tissue, indicating a potential CV protec-
tive effect [18, 19]. Several mega-clinical trials designed 
to clarify the effects of SGLT2 inhibitors on clinical 
CV outcomes are now in progress [20]. Of these trials, 
EMPA-REG OUTCOME trial showed that empagliflozin 
markedly reduced the risk of CV mortality compared to 
placebo [21]. Although CV mortality and worsening of 
heart failure were both decreased dramatically, empagli-
flozin treatment failed to reduce macro-vascular events, 
such as non-fatal myocardial infarction and stroke. The 
clinical impact of SGLT2 inhibitors on CV benefits has 
therefore attracted considerable attention, although the 
mechanisms by which SGLT2 inhibitors exert these ben-
efits beyond glucose-lowering are not fully understood. 
In particular, clinical evidence regarding the therapeutic 
effect of SGLT2 inhibitors on arteriosclerosis in patients 
with diabetes is still lacking. The effects on arterioscle-
rosis of other anti-diabetic agents, such as pioglitazone 
and dipeptidyl peptidase 4 (DPP-4) inhibitors, have been 
evaluated in randomized clinical trials using surrogate 
markers, such as carotid intima-media thickness (IMT) 
[22–25]. This method is well-established and has good 
reproducibility and reliability to reflect the clinical sever-
ity of systemic atherosclerosis, and is therefore useful for 
evaluating drug efficacy.
On the basis of this background, the PROTECT study 
was designed to evaluate the anti-atherosclerotic effect 
of ipragliflozin using IMT as a surrogate marker for the 
risk of CV events and also to clarify the mechanisms by 
which SGLT2 inhibitors may improve CV outcomes. 
This study may provide novel evidence regarding SGLT2 




The PROTECT study is an ongoing, multicenter, pro-
spective, randomized, open-label, blinded-endpoint, 
parallel group, investigator-initiated clinical trial (phase 
IV). The study will test the hypothesis that compared 
to standard care alone, the addition of ipragliflozin to 
standard care in T2DM may suppress the progression of 
carotid atherosclerosis, accompanied by an improvement 
in glycemic and lipid metabolism and vascular function. 
After recruitment and randomization of the patients into 
groups with or without ipragliflozin, each treatment is 
continued for 24  months, and the long-term safety and 
effects of ipragliflozin on CV systems then evaluated.
The study protocol was approved by the local institu-
tional review boards and independent ethics committees. 
The study will be conducted in full compliance with the 
articles of the Declaration of Helsinki and according to 
the Ethical Guidelines for Medical and Health Research 
Involving Human Subjects established by the Ministry of 
Health, Labour, and Welfare and Ministry of Education, 
Culture, Sports, Science, and Technology. The PROTECT 
study was registered by the UMIN in July 2015 (ID: 
000018440).
Keywords: Atherosclerosis, Intima‑media thickness (IMT), Ipragliflozin, SGLT2 inhibitor, Type 2 diabetes mellitus
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Study population and recruitment
We aim to recruit a total of 480 participants across 
approximately 35 sites in Japan. Recruitment for the 
study began in September 2015 and will end in Decem-
ber 2017. Eligible participants for the study are T2DM 
patients who comply with all the enrollment criteria. 
The detailed inclusion and exclusion criteria are listed in 
Table 1. Briefly, patients will be enrolled if they are aged 
≥20 year, diagnosed as having T2DM in accordance with 
the Japanese guidelines [26], with a HbA1c between 6.0 
and 10.0 % despite diet and exercise therapy and/or tak-
ing standard medications for at least 3  months prior to 
randomization. After initial screening using previous 
medical records, each participant is required to receive 
an adequate explanation of the study plan, with written 
informed consent then being obtained.
Study outline and follow up
After informed consent has been obtained and the eli-
gibility assessment is completed, all eligible participants 
will be randomized and assigned into either the ipragli-
flozin group or standard-care (control) group. Follow-up 
visits are scheduled at 3, 6, 12 and 24 months (Fig. 1). All 
participants will see their usual-care physicians at each 
visit to receive usual-care and individualized appropriate 
treatment according to their background disease, in addi-
tion to administration of the study drug.
Randomization and treatment
Eligible participants with appropriately signed informed 
consent will be randomized to either the ipragliflozin 
group or control group (ratio 1:1) using the web-based 
minimization method with biased coin assignment bal-
ancing [27, 28] for age (<65, ≥65 year), HbA1c level (<7.0, 
≥7.0 %), systolic BP (<135, ≥135 mmHg), use of statins, 
and use of biguanides at the time of screening.
All participants will be followed-up for 24  months. 
Although a specific numerical goal in glycemic control 
such as HbA1c level is not set for the study, all partici-
pants need to be treated to achieve a personalized goal 
recommended by the treatment guideline in Japan (details 
in Additional file 1) [26]. Participants who are assigned to 
the ipragliflozin group receive ipragliflozin 50  mg once 
daily in addition to their background medical therapy. 
In accordance with official recommendation regarding 
use of SGLT2 inhibitor from the Japan Diabetes Society 
[29], patients aged ≥75  years should be most carefully 
followed up with particular attention to development of 
volume depletion-related adverse drug reactions [30]. If 
the personalized goal is not achieved, the dose of ipra-
gliflozin can be increased by the investigators to 100 mg 
once daily. Participants who are assigned to the control 
group continue their background therapy. Within the 
appropriate range of the therapeutic goal, the participant’s 
background therapy will be, in principle and if possible, 
unchanged during the study in both groups. However, 
if participants cannot achieve their glycemic goal, co-
administration of anti-diabetic agents other than SGLT2 
inhibitors or increased dosages of the other anti-diabetic 
agents in both groups may be considered by investigators, 
with caution being taken to prevent the development of 
hypoglycemia. However, because pioglitazone is known 
Table 1 Detailed inclusion and exclusion criteria
CHF chronic heart failure, eGFR estimated glomerular filtration rate, NYHA New York Heart Association, SGLT2 sodium glucose cotransporter 2, T2DM type 2 diabetes 
mellitus
Inclusion Exclusion
Adults (aged ≥20 years) Type 1 diabetes mellitus
T2DM with 6.0 % ≤ HbA1c < 10.0 % despite diet and 
exercise therapy and/or the standard medications 
for at least 3 months prior to randomization
History of severe ketosis, diabetic coma, or
The patient provided written informed consent to 
participate in the study
Precoma attack ≤6 months prior to informed consent
Patients with severe infection or trauma at trial screening
Patients in perioperative period around trial screening
Severe renal dysfunction (eGFR < 45 ml/min/1.73 m2) or patients receiving dialysis
History of coronary artery disease, coronary vascularization, open‑heart surgery, stroke, or tran‑
sient ischemic attack ≤3 months prior to eligibility
CHF (NYHA functional classification III and IV)
History of administration of SGLT2 inhibitor 1 month prior to study initiation
Pregnant or suspected pregnancy in females
Lactating female
History of hypersensitivity to ingredients of ipragliflozin
Considered inappropriate for the study by investigators due to other reasons, such as malignancy
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to have a suppressive effect on the progression of IMT, 
compared to glimepiride [22], it is prohibited to prescribe 
it or change its dose during the study. After the study is 
completed, all participants can continue any anti-diabetic 
treatment in accordance with their individual condition.
Measurements
Baseline characteristics, including gender, age, body 
height and weight, abdominal circumference, complica-
tions, duration of T2DM, background treatment, and 
smoking and drinking habits will be recorded prior to 
randomization. The status of the study medications and 
the participant’s background treatment will be recorded 
at each visit. Measurements of BP, pulse rate, BW, and 
body mass index (BMI) will also be carried out at base-
line and after 12 and 24 months. Abdominal circumfer-
ence will be measured at baseline and 24 months. Blood 
tests without HbA1c level will be checked at baseline 
and 24 months (details listed in Additional file 2); HbA1c 
will be measured at baseline and after 12 and 24 months. 
Specific biomarkers such as N-terminal pro-brain natriu-
retic peptide (NT-proBNP), high-sensitivity C reactive 
protein (hsCRP), high-molecular weight adiponectin, 
and malondialdehyde modified low-density lipoprotein 
(MDA-LDL) will be measured at baseline and 24 months. 
Creatinine-corrected urinary albumin excretion will be 
measured at baseline and 24  months (optional). Some 
optional imaging and physiological tests are also planned 
in the study including abdominal computed tomogra-
phy to measure the amount of visceral and subcutane-
ous fat, echocardiograms, flow-mediated dilation (FMD), 
pulse-wave velocity (PWV), cardio-ankle vascular index 
(CAVI), and augmentation index (AI) (details listed in 
Additional file 3).
Measurement of carotid IMT
The protocol and method for measuring carotid IMT 
have been described in detail previously [25, 31, 32]. 
In brief, the carotid ultrasound examinations using 
standardized imaging protocols and systems equipped 
with >7.5  MHz linear transducers will be performed at 
each local site and then measured at a core laboratory 
(Tsukuba University) at baseline and 24  months after 
randomization. Expert trained sonographers who have 
attended a lecture on measuring carotid IMT will carry 
out the procedure according to the Mannheim carotid 
IMT consensus [33, 34]. The head position and probe 
angle of the ultrasound approach will be set using a 
ruler located just cephalad (Fig. 2). Longitudinal B-mode 
images, perpendicular to the ultrasound beam, with a 
3–4  cm imaging depth, will be recorded in the distal 
common carotid arteries (CCA), carotid bulbs, and prox-
imal internal carotid arteries (ICA) on both sides. The 
lateral probe incidence is used to obtain CCA images, 
using external landmarks and an original semicircular 
protractor developed for this purpose. The mean CCA-
IMT indicates the average IMT value of the right and left 
CCA-IMT, 10 mm from the bulb. The following far wall 
IMTs will be measured; maximum IMT of the CCA and 
mean and maximum IMTs of the bulb and ICA. The opti-
mized R-wave gated still frames of the carotid IMT will 
be stored as JPEG files, with all the parameters collected 
and measured at the core laboratory. An expert analyzer 
blinded to the allocation and clinical information of the 
subjects will measure all the IMT values using an auto-
matic IMT measurement software program (Vascular 
Research Tools 5, Medical Imaging Applications, Iowa, 
USA) [35]. The software program identifies the lumen/
intima and the media/adventitia borders in this region 
and calculates the distance between them.
Safety
Based on the intention-to-treat the entire population, 
safety will be checked by recording the following adverse 
effects (AEs) throughout the study: severe AEs regardless 
as to whether or not there is causal relationship between 
the AEs and the study; and relevant AEs such as hypo-
glycemia, genital or urinary tract infections, ketoacido-
sis, and hypovolemic symptoms. When the investigators 
confirm these AEs, the grade of severity, procedures, 
outcomes, and relationship to the study drug will be 
assessed. A prompt report to the study secretariat and 
to the Data and Safety Monitoring Board (DSMB) will 
then be made by the trial organizer. The members of the 
DSMB consist of authorized endocrinologists, cardiolo-
gists, or neurologist with relevant expertise. The criteria 
for withdrawal from the trial are listed in Table  2. The 
incident of withdrawal from the study will be reported 
promptly to the DSMB by the chief investigator. The 
DSMB will then deliberate on the incident and report the 
decision to the chief investigator.
Control
(without SGLT2 inhibitor)
Ipragliflozin, 50 mg/day 









Background therapy for T2DM and other complicaons
3
Fig. 1 Study outline
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Study endpoints
Intima-media thickness (IMT) in the carotid artery is 
well-established as a surrogate marker for risk of CV dis-
eases and is also useful for evaluating the effectiveness 
of various types of therapeutic interventions in patients 
with or without T2DM [35–37]. The primary endpoint in 
the study is the change in mean IMT of the CCA from 
baseline to 24 months. The secondary endpoints are the 
values and changes in parameters after 24  months of 
treatment, including: (1) mean IMT of the bulb and ICA, 
(2) max IMT of the CCA, bulb, and ICA, (3) the over-
all mean of mean IMT of the CCA, bulb, and ICA, (4) 
the mean of max IMT of the CCA, bulb, and ICA, (5) 
specific biomarkers including hsCRP, MDA-LDL, NT-
proBNP, and high-molecular weight adiponectin, (6) the 
cardiovascular functional tests listed in Additional file 3 
(optional), (7) abdominal circumference and amount of 
visceral and subcutaneous fat measured by abdominal 
computed tomography (optional), (8) creatinine-cor-
rected urinary albumin excretion. In addition, the values 
and changes after 12 and 24  months in several clinical 
parameters including BP, BW, and BMI and laboratory 
data (details listed in Additional file 2) will be evaluated. 
Safety endpoints also include AEs and adverse drug reac-
tions observed during the study.
Statistical considerations
Sample size estimation
Due to the lack of data on the effect of SGLT2 inhibitors 
on carotid IMT, we referred to the statistical data from 
the CHICAGO study [22] and PROLOGUE study [25]. 
In the CHICAGO study, pioglitazone caused a significant 
inhibition of the progression of CCA-IMT (−0.0010 mm 
after 72  weeks), compared to glimepiride (+0.0120  mm 
after 72 weeks). We estimated the changes from baseline 
would be −0.0013  mm (pioglitazone) and +0.016  mm 
(glimepiride) after 96  weeks. Based on the assumption 
that ipragliflozin may inhibit the progression of CCA-
IMT to the same extent as pioglitazone, we estimated the 
group difference as 0.016 (ipragliflozin −0.001 and con-
trol +0.015) ±0.06 (standard deviation). At a significant 
level of 5 % (two-sided), the sample size of 222 patients 
Fig. 2 Method for measuring IMT. a Head position is set at 45° toward the other side (right) when measuring at the left carotid artery. b The probe 
angle is also set at 45° using the ruler on the test side. c A plus B. d Schema for measuring the left carotid artery. The probe is set perpendicular to 
the sagittal plane
Table 2 Discontinuance criteria
Severe hypoglycemia
Seriously poor glycemic control such as ≥HbA1c 12.0 % confirmed by 
second measurement on different day
Offer for participation declined by participants
Deviancy of eligibility after registration
Considered inappropriate to continue the study by investigators due to 
aggravation of primary disease or complications
Considered inappropriate to continue the study by investigators due to 
adverse side effects of the study drug
Pregnant
Poor drug adherence (<75 %, or >120 %)
Considered inappropriate to continue the study by investigators due to 
some other reason
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per arm provides a power of 80 % for each comparison. 
Allowing for a dropout rate of 5 %, 240 patients in each 
arm (a total of 480 patients) provides sufficient statistical 
power for the study.
Statistical analysis plan
The analyses of the primary and secondary endpoints 
will be performed in the full analysis set (FAS), which 
includes all participants who received at least one dose 
of treatment during the study period and did not have 
any serious violation of the study protocol such as not 
providing informed consent, registration outside of the 
study period, or data collected after commencement of 
treatment.
Summary statistics will be calculated for the baseline 
characteristics including the frequencies and proportions 
for categorical variables and means  ±  standard devia-
tions for continuous variables. The patient characteristics 
will be compared using Chi square tests for categori-
cal variables, t tests for normally distributed continuous 
variables, or the Wilcoxon rank sum tests for continuous 
variables with a skewed distribution.
The analysis plan is similar to that used in previous 
studies we have conducted [25, 31, 32]. In brief, for the 
primary analysis comparing treatment effects, the base-
line-adjusted means and their 95  % confidence inter-
vals, estimated by analysis of covariance of the change 
in average carotid IMT at 24 months, will be compared 
between the treatment groups (ipragliflozin group vs. 
control group). The results will be adjusted by allocation 
factors. The primary analysis will not include missing 
observations, with the mixed effects model for repeated 
measures (MMRM) being used as a sensitivity analysis to 
examine the effect of missing data. In addition, MMRM 
will be used as a sensitivity analysis to examine the out-
comes at baseline and 24 months modelled as a function 
of time, treatment, and treatment-by-time interaction. 
The secondary analysis will be performed in the same 
manner as the primary analysis.
All comparisons are planned and all P values will be 
two sided. P values <0.05 will be considered statistically 
significant. All statistical analyses will be performed 
using SAS software version 9.4 (SAS Institute, Cary, NC, 
USA). The statistical analysis plan will be developed by 
the principal investigator and a biostatistician before 
completion of patient recruitment and database lock.
Study organization and oversight
The principal investigators of the PROTECT study are 
(details in Additional file 4) Koichi Node (Chief ), Depart-
ment of Cardiovascular Medicine, Saga University and 
Toyoaki Murohara, Department of Cardiology, Nagoya 
University Graduate School of Medicine. The research 
advisor is Masafumi Kitakaze, Department of Clinical 
Medicine and Development, National Cerebral and Car-
diovascular Center. The steering committee will carry 
out planning, operating, analyzing, and presentation of 
the trial. The executive committee will supervise the trial 
design and operation of the study. The roles of the DSMB 
are described in the section on Safety. The trial secre-
tariat is in DOT INTERNATIONAL CO., LTD, Tokyo, 
Japan. Each data management, monitoring, statistical 
analyses, and audit will be implemented independently 
on the basis of the outsourcing agreement. Carotid IMT 
will be measured at a core laboratory, Tsukuba University. 
Data monitoring will be enforced to ensure the research 
is performed properly, with an independent audit team 
inspecting several main institutes to ensure the quality of 
the study data.
Discussion
The PROTECT study is an ongoing, multicenter, prospec-
tive, randomized, investigator-initiated clinical trial that 
has the aim of assessing the add-on effect of ipragliflozin 
using carotid IMT as a surrogate marker of CV risk. Car-
diac and vascular functional tests will also be evaluated 
as secondary endpoints. Eligible patients with T2DM will 
be assigned to ipragliflozin or conventional standard care 
groups. The primary endpoint is the change in mean IMT 
of the CCA from baseline to 24 months of treatment. The 
study has the potential to provide novel clinical evidence 
on the anti-atherosclerotic effect of ipragliflozin.
Carotid IMT is used widely as a noninvasive meas-
ure of systemic atherosclerotic state and to predict sub-
sequent CV events and mortality [38, 39]. A number of 
studies have demonstrated that increased IMT corre-
lates strongly with the risk of future CV disease in a wide 
range of populations, especially T2DM patients [40–44]. 
Measuring carotid IMT is also recognized as a useful sur-
rogate marker for evaluating the efficacy of therapeutic 
interventions on CV risk factors and atherosclerotic dis-
eases [37, 45–47]. Although the current study is a mul-
ticenter open-label design, repeated IMT measurements 
are planned in a blinded manner. The analyses will be 
carried out at a core laboratory according to global rec-
ommendations in order to avoid bias and measurement 
error between institutions [48]. The same systematic 
procedures for analysis of carotid IMT were used in our 
previous and other ongoing studies [25, 31, 32]. The reli-
ability and reproducibility of measurements of carotid 
IMT will be highly certified in the current study.
Because diabetes contributes strongly to accelerated 
progression of carotid IMT [49], the inhibitory effects of 
several anti-diabetic agents on carotid IMT progression 
have been investigated extensively. In the CHICAGO 
study [22], mean and max carotid IMT progression was 
Page 7 of 11Tanaka et al. Cardiovasc Diabetol  (2016) 15:133 
significantly lower in the pioglitazone group compared 
to the glimepiride group. This inhibitory effect has been 
confirmed in other clinical trials [50] and is, in part, con-
sistent with the result from a large-scale outcome study, 
the Prospective Pioglitazone Clinical Trial in Macrovas-
cular Events (PROactive). That study demonstrated that 
the addition of pioglitazone was associated with a 16  % 
risk reduction in the composite of all-cause mortality and 
non-fatal macro-vascular events compared to the addi-
tion of placebo [51]. Even in the IGT subjects, acarbose, 
an alpha-glucosidase inhibitor, also attenuated signifi-
cantly the mean IMT progression relative to placebo [52]. 
This result may provide a possible mechanism by which 
acarbose reduced the incidence of cardiovascular events 
in the earlier trial [53]. Regarding DPP-4 inhibitors, 
the TECOS trial that evaluated CV outcomes in 14,671 
T2DM patients with established CV disease showed a 
neutral effect of sitagliptin on the risk of major adverse 
CV events during a median follow-up of 3  years [54]. 
The other outcome mega-trials that evaluated CV safety 
of DPP-4 inhibitors, the EXAMINE and SAVOR-TIMI 
53 studies, also showed similar results [55, 56]. Inter-
estingly, in the Program of Vascular Evaluation under 
Glucose Control by a DPP-4 Inhibitor (PROLOGUE), sit-
agliptin failed to inhibit the progression of carotid IMT 
compared to standard diabetes care during 24  months 
of follow-up [25]. In contrast, other studies of DPP-4 
inhibitors have demonstrated a beneficial effect on pro-
gression of carotid IMT [23, 24]. The reasons for this 
discrepancy remain uncertain, although clinical differ-
ences in the patients’ background, such as concomitant 
drugs and severity of diabetes and CV risk may, in part, 
influence the effectiveness of DPP-4 inhibitors on carotid 
atherosclerosis. Recent clinical trials also clearly show a 
close association between anti-diabetic agents-mediated 
changes in carotid IMT and CV outcomes in the majority 
of T2DM patients.
SGLT2 inhibitors are a novel class of oral anti-dia-
betic agent that lower blood glucose level by increasing 
urinary glucose excretion. In addition to the glycemic 
pathway, SGLT2 inhibitors are associated closely with 
non-glycemic modifications, such as hemodynamic, 
metabolic, renal, and neurohormonal effects [20, 57]. In 
2015, the EMPA-REG OUTCOME trial reported out-
standing results that the SGLT2 inhibitor, empagliflo-
zin, markedly improved clinical outcomes in diabetes 
patients with a higher CV risk [21]. Because other out-
come trials using SGLT2 inhibitors other than empa-
gliflozin are now ongoing [58–60], it still remains to be 
determined whether this clinical impact is a class effect 
of SGLT2 inhibitors. However, given their mode of action 
and favorable effects on the entire CV system, it is very 
likely that further positive evidence may be obtained 
[61]. In the EMPA-REG OUTCOME trial, empagliflozin 
caused a significant reduction in CV mortality and hos-
pitalization for worsened heart failure rather than mac-
rovascular complications, such as non-fatal myocardial 
infarction and stroke. Based on these beneficial clinical 
outcomes, possible mechanisms may be largely hemo-
dynamic effects induced by glycosuria and natriuresis, 
rather than a direct anti-atherothrombotic effect [62–64]. 
However, SGLT2 inhibitors ameliorate various risk fac-
tors related to CV disease, such as BP, BW, uric acid, and 
lipid profiles independent of glycemic control per sé, 
suggesting the possible existence of anti-atherosclerotic 
actions. Indeed, there is evidence that SGLT2 inhibitors 
prevent excess oxidative stress and inflammation in ani-
mal models [65–69]. In clinical studies, direct effects on 
arterial stiffness were also observed in patients with type 
1and type 2 diabetes [70, 71]. Although the increased 
incidence of non-fatal stroke was reported in the EMPA-
REG OUTCOME trial and subsequent meta-analyses 
[21, 61], the study duration may have been too short to 
prevent the occurrence of atherogenic macro-vascular 
events, including stroke. Importantly, the precise effects 
of SGLT2 inhibitor on local and systemic atherosclerosis 
in clinical settings have proved elusive. It would therefore 
be plausible to implement a mechanistic study using a 
surrogate marker as a study endpoint.
In the current study, we are attempting to assess the 
preventive effect of a SGLT2 inhibitor, ipragliflozin, on 
carotid IMT progression. In 2014, ipragliflozin was the 
first SGLT2 inhibitor to be released in Japan [19]. Tahara 
et al. [72] reported that compared to other SGLT2 inhibi-
tors, ipragliflozin had a relatively longer-acting and 
earlier-onset of action on renal SGLT2. Accumulated evi-
dence from the initial clinical studies in Japanese T2DM 
patients also showed short- and long-term favorable 
effects of ipragliflozin on glycemic, metabolic, and safety 
parameters [30, 73–77]. Takahara et al. [78] also reported 
that ipragliflozin treatment improved pancreatic beta-cell 
dysfunction and subsequent insulin resistance in T2DM 
patients, similar to that reported for other SGLT2 inhibi-
tors [79, 80]. Systemic insulin resistance (IR) plays a piv-
otal role in the pathogenesis and progression of obesity 
and noninsulin-dependent diabetes mellitus [81]. It is 
also known that insulin resistance and resultant diabetes 
are associated closely with non-alcoholic fatty liver dis-
ease (NAFLD), including non-alcoholic steatohepatitis 
(NASH); a progressive phenotype in the NAFLD spec-
trum [82–84]. Recent animal studies showed that ipra-
gliflozin treatment attenuated liver dysfunction mediated 
by steatosis and fibrosis in some rodent models of NASH 
[85, 86]. Because SGLT2 is not expressed in the liver, such 
treatment effects may be caused indirectly by ameliora-
tion of systemic IR and inflammation. Treatment with a 
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SGLT2 inhibitor therefore has the potential to improve 
obesity and diabetes-associated metabolic abnormalities 
in the entire body, suggesting the possibility of an anti-
atherosclerotic action.
This study has several limitations. First, the PROTECT 
study is not a double blind placebo-controlled trial, but 
rather an open label design. Unexpected bias towards the 
assessment of outcomes resulting from the physicians’ 
choice of treatment may occur. To avoid this possible bias, 
there are strict requirements that the participants’ back-
ground treatment will, in principle and if possible, remain 
unchanged during the study. In addition, carotid IMT, a 
key endpoint in the study, will be measured at a central 
laboratory, and all the data will be managed and statisti-
cally analyzed in a blinded fashion. Second, because the 
duration of the study is 24 months, it is possible the addi-
tional anti-diabetic agents administered when glycemic 
control becomes worse, especially in the control group, 
may influence outcomes. It is therefore important to take 
into account that pioglitazone and some other DPP-4 
inhibitors may also prevent progression of carotid IMT 
in patients with T2DM [22–24]. Third, because the inves-
tigators who are participating in the PROTECT study are 
mainly cardiologists, there may be potential variety of 
treatment or judgement in the management of diabetes. 
Therefore, the Steering Committee recommends clini-
cal practice will be performed according to the partici-
pants’ comprehensive conditions based on the treatment 
guideline in Japan [26]. Last, patient’s renal function, esti-
mated glomerular filtration rate (eGFR), is not included 
as an allocation factor, although patients with severe 
renal dysfunction (eGFR < 45 ml/min/1.73 m2) or receiv-
ing dialysis are excluded. The patient’s kidney function is 
one of major determinants of urinary glucose excretion 
by SGLT2 inhibitor treatment. Previous studies reported 
that urinary glucose excretion in patients with lower lev-
els of eGFR was actually decreased, and improvement of 
glycemic control was lower than patients without impair-
ment of renal function [87, 88]. However, there were 
SGLT2 inhibitor-induced reductions in body weight and 
blood pressure independently of patient’s renal function 
[89]. Thus, we have speculated that anti-atherosclerotic 
effect may be, in part, caused by ipragliflozin indepen-
dently of glycemic control and renal function at baseline.
In summary, the PROTECT study is the first to evalu-
ate the effect of ipragliflozin on carotid IMT in patients 
with T2DM. Clear evidence of the therapeutic effects of 
SGLT2 inhibitors on atherosclerosis is currently lack-
ing in clinical settings. Given the multi-factorial effects 
of SGLT2 inhibitors independent of glycemic control, it 
is not unexpected that ipragliflozin is able to exert a pro-
tective action against the atherosclerotic process. This 
study has the potential to provide new knowledge on 
effective treatment to prevent atherogenic complications 
in patients with T2DM.
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